Altimmune (0A4C) AI Stock Analysis

0 Followers

Altimmune

(LSE:0A4C)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Clinical pipeline progressPositive mid-stage data across several liver-disease measures supports pemvidutide’s clinical differentiation and gives Altimmune a credible basis for advancing development. If replicated in later trials, the breadth of observed effects could support a durable liver-focused franchise rather than a single-indication opportunity.

Negative Factors

Pre-commercial financial profileAltimmune has not yet demonstrated recurring product revenue, while its research-led cost base produces substantial losses. This leaves future financial performance dependent on clinical success, financing, collaborations, or commercialization, making the path to self-sustaining operations uncertain over the next several quarters.

Altimmune (0A4C) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $375.42M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -2.3
Beta (1Y): 1.04
Revenue Growth: 30.00%
EPS Growth: 31.68%
Country: UK
Employees: 57
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Altimmune Business Overview & Revenue Model

Company Description

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/gluc...

Altimmune Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:May 14, 2019

Earnings Call SentimentPositive

The call was strongly optimistic about pemvidutide's clinical differentiation and development progress. Management highlighted positive MASH and AUD data, expanding clinical execution, strong investigator engagement, a substantial AUD opportunity, and sufficient cash runway through the planned MASH readout. The principal negatives were higher operating expenses, a larger absolute quarterly net loss, low MASH diagnosis and treatment rates, ongoing tolerability evaluation, and the lack of a firm AUD Phase 3 start date or funding plan. Overall, the highlights significantly outweighed the lowlights.

Positive Updates

Pemvidutide Development Progress Across Three Liver Indications

Management said it significantly advanced pemvidutide programs across NASH, AUD, and ALD during 2026, strengthening its belief that the product can support a broad liver franchise with multiple indications in serious liver diseases.

Negative Updates

Higher Research and Development Expense

Q3 2026 R&D expense was $27 million versus $15 million in the prior-year period, an increase of approximately 80%. Management attributed the increase primarily to initiation of the Phase 3 NASH trial and the ongoing Phase 2 ALD trial. Direct pemvidutide development costs were $20.3 million, including $10.7 million for NASH, $4.3 million for the Phase 2 ALD and AUD trials, and $5.4 million in CMC-related expenses.

Company Guidance

Management expects the PERFORMA 52-week data readout in 2029, with enrollment taking an 18 to 24 month range; over 70 US sites are activated, roughly 1 third of the ultimate study sites will be in The US, and ex US sites are expected to activate over the coming months. For AUD, the end of phase 2 meeting with the FDA is scheduled for December, meeting minutes typically follow within 30 days, and EMA dialogue is anticipated in the first quarter; the expected PROCURE design includes 1.8 milligram and 4 mg doses with a simple 1 to 2 step titration, a primary efficacy read at 26 weeks, and continuation up to 1 year. RESTORE top line data are expected in the second half of 27, and $480 million in cash equivalents and investments is expected to provide operating runway through the PERFORMA Phase 3 MASH 52-week data readout expected in 2029.

Altimmune Risk Analysis

Altimmune disclosed 65 risk factors in its most recent earnings report. Altimmune reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Altimmune Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0A4C against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SGMT	55Neutral	$802.59M	-9.20	-29.95%	―	―	33.38%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORMP	51Neutral	$171.80M	0.95	72.96%	―	-100.00%	―
ARCT	46Neutral	$268.34M	-2.77	-46.79%	―	-74.84%	-25.04%
GALT	44Neutral	$331.80M	-7.28	21.48%	―	―	33.25%
BIOA	41Neutral	$269.78M	-2.23	-31.42%	―	45.33%	-20.81%

* Healthcare Sector Average

Performance Comparison

GB:0A4C and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0A4C	Altimmune	2.89	-1.26	-30.39%
GALT	Galectin Therapeutics (GALT)	3.14	-2.37	-43.01%
ARCT	Arcturus Therapeutics	8.44	1.17	16.09%
ORMP	Oramed Pharmaceuticals Inc	4.03	1.86	85.54%
SGMT	Sagimet Biosciences, Inc. Class A	10.93	3.18	41.03%
BIOA	BioAge Labs, Inc.	5.65	-2.15	-27.56%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Altimmune AI Stock Analysis